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Abstract. We searched for methods that would enable 
prescriptions of the maximum tolerable doses of iodine- 
131 metaiodobenzylguanidine (MIBG) and iodine-125 
MIBG in the treatment of patients with neuroblastoma. 
We correlated doses, defined in different ways, with 
subsequent platelet levels in treated patients to deter- 
mine accurate predictors of the most frequent toxicity, 
thrombocytopenia. Nine patients with neuroblastoma 
were given 13q-MIBG (4.9-8.1 GBq or 132-220 mCi) 
and ten were given 125I-MIBG (8.3-30.0 GBq or 224- 
809 mCi) as initial treatments. These therapies were 
sufficiently varied that correlations could be made be- 
tween indices of the doses and the subsequent toxicity 
as reflected in circulating platelet levels. Predictors of 
toxicity were: whole-body absorbed dose of radiation 
(cGy) calculated from pretherapy tracer doses of 131I- 
MIBG; GBq/kg of body weight; and GBq/m 2 of body 
surface area. Toxicity was recorded as the nadir of the 
platelet level and platelet/pretherapeutic level (platelet 
ratio). For treatments with 13~I-MIBG, the highest cor- 
relation was obtained between cGy and the log~0-trans- 
formed platelet ratio (r=--0.86), but comparison of 
GBq/m 2 and the platelet nadir (r=-0.76) or the platelet 
ratio (r=-0.74) or the log~o transformed platelet ratio 
(r=-0.73) gave comparable and statistically significant 
results. For treatments with 12SI-MIBG, significant cor- 
relations were obtained between GBq/m 2 and the plate- 
let ratio (r=-0.81) or GBq/kg and the lOgl0--transformed 
platelet ratio; the correlation between cGy and any tox- 
icity index was low. Per administered GBq, 13~I-MIBG 
was 2.6 times more potent than ~25I-MIBG in causing a 
platelet ratio of 0.1. Thus, in predicting toxicity, ther- 
apeutic doses of 13~I-MIBG expressed as GBq/m 2 per- 
formed satisfactorily and almost as well as whole-body 
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cGy, and treatment doses of laSI-MIBG expressed as 
GBq/m 2 or GBq/kg performed satisfactorily and much 
better than whole-body cGy. 
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I n t r o d u c t i o n  
Radiolabeled metaiodobenzylguanidine (MIBG) has 
been introduced as therapy for patients with advanced 
neuroblastoma because other treatments have failed to 
effect cures and because the concept of delivering radia- 
tion selectively to the tumors - via the sequestration of 
MIBG - is compelling. Therapies with 13tI-MIBG ap- 
peared to cause regressions of tumors in about one- 
fourth of the treated patients; there were a few complete 
remissions, but no cures [1-11]. To attack the micro- 
metastases that may be the source of recurrences fol- 
lowing 131I-MIBG treatments, 125I-MIBG, which can im- 
part more confined radiation energy within small neo- 
plastic deposits, was given as a therapeutic agent in a 
phase I/II trial [12, 13]. 
If the radiolabeled MIBGs are to have a role in the 
treatment of neuroblastoma, optimum effects are likely 
to occur only when the agents are given in large doses 
that result in some toxicity to normal tissues. On the 
other hand, current practice is not to produce such 
severe toxicity that the most vulnerable organ, the bone 
marrow, fails to maintain function. Within this guide- 
line, thrombocytopenia, the most sensitive expression 
of radiation injury from the radiopharmaceuticals [1, 6, 
12-14], particularly must not become life threatening. 
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Therefore,  a rel iable predictor of bone  marrow tox- 
icity is necessary if aggressive therapies with 131I-MIBG 
and/or  t25I-MIBG are to be pursued. We report here on 
our analyses of  the toxic consequences  of  treatments,  
at varied adminis tered  doses of ~31I-MIBG and ~25I- 
MIBG,  and derive indices that predict  thrombocyto-  
penia.  
Materials and methods 
Patients. Data on six of the patients treated with 13JI-MIBG have 
been reported in part elsewhere [14]. Three additional patients 
were treated with 131I-MIBG. They were recruited for 125I-MIBG 
treatment; however, because 125I was not available in sufficient 
quantities for synthesis of the radiopharmaceutical at the time of 
treatment, these patients were given 131I-MIBG instead. Clinical 
information on seven of the patients has been included in other 
publications [7, 15]. 
Ten subjects were recruited for 125I-M1BG treatment from pe- 
diatric oncologists around the United States. Entry criteria for 
treatment with 125I-MIBG were as described before, but also in- 
cluded patients with progressive disease [12]. Preliminary data 
on the first seven patients in the I25I-MIBG treated group have 
also been reported previously [12, 13]. No patient had received 
prior therapy with a radiolabeled MIBG. The patients exhibited 
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little (less than 25%) or no bone marrow involvement by the 
neuroblastoma. Levels of peripheral blood elements including 
platelets were measured by standard automated techniques. 
This investigation was approved by Internal Review Board at 
the University of Michigan Medical Center. 
Radiopharmaceuticals. Syntheses of 13JI-MIBG and I25I-MIBG 
were carried out as previously described [12, 16, 17]. For diag- 
nostic doses 131I-MIBG was prepared at 0.12-0.13 GBq/mg, 
mean 0.12 GBq/mg (1.1 Ci/mmot). For therapies the specific ac- 
tivities were 1.0-1.94 GBq/mg (9.l-17.4 Ci/mmol) for 1311- 
MIBG and 40.0-63.8GBq/mg (13.3-21.3 Ci/mmol) for 1251- 
MIBG. These values can be calculated for individual patients 
from the data in Table 1. 
Dosimetl~y,. Methods of dosimetry using 131I-MIBG have also 
been previously described [12, 14]. Briefly, 131I-MIBG, 0.063 
GBq/m 2 of body surface area, was infused over 90 rain. Whole- 
body counting for residual radioactivity using a scintillation probe 
at 2 m was performed shortly after completion of the infusion to 
give a 100% value and again after voiding urine at 3 h. The 
geometric means of anterior and posterior counts were used in 
calculations. Subsequent measurements were made daily from 1 
through 6 or 7 days. Blood samples were obtained immediately 
following the infusion, at 3 h and then daily at the time of meas- 
urements of whole-body retention. Whole blood specimens were 
counted in a well counter. 
Table 1. Data on individual therapies 
Patient Weight Surface MIBG administered doses 
(kg) area 
(m 2) mga GBq GBq/kg GBq/m 2 
Absorbed radiation Circulating platelets 
Whole Blood Nadir Ratio b 
body (cGy) (thousands) 
(cGy) 
A. 131I_MIBG Therapaes 
1 14 0.59 5.1 5.14 0.366 8.66 
2 19.8 0.77 4.3 7.51 0.381 19.8 
3 19.8 0.83 5.1 7.40 0.374 8.95 
4 11.4 0.51 3.3 4.88 0.429 9.58 
5 20 0.82 4.7 7.84 0.392 9.51 
6 56.6 1.61 4.2 8.14 0.144 5.07 
7 19.8 0.83 3.4 6.88 0.347 8.33 
8 15.5 0.70 4.1 6.48 0.422 9.25 
9 18.5 0.75 4.9 7.40 0.400 9.92 
B. J25I-MIBG Therapies 
l 14.9 0.69 6.1 13.7 0.899 20.0 
2 c 13.8 0.60 5.8 9.66 0.699 16.1 
3 15.7 0.64 8.9 15.1 0.958 23.5 
4 d 21.2 0.86 8.9 19.7 0.929 23.0 
5 15.7 0.64 8.9 20.0 1.27 31.5 
6 d 18.1 0.75 8.2 14.8 0.821 19.9 
7 d 42.6 1.38 14.6 29.9 0.703 21.8 
8 15.5 0.68 7.6 16.0 1.03 23.3 
9 c 18.2 0.69 5.9 8.29 0.459 12.0 
10 26.8 1.02 17.7 30.1 1.12 29.5 
231 l l0  89 0.30 
183 88 57 0.26 
180 76 173 0.45 
170 84 131 0.45 
132 - 116 0.29 
103 59 342 0.97 
179 - 233 0.73 
201 - 78 0.27 
305 - 10 0.11 
105 69 16 0.11 
83 55 176 0.49 
104 73 207 0.50 
133 89 58 0.25 
118 82 7 0.017 
105 69 43 0.23 
84 61 66 0.35 
120 - 27 0.17 
119 80 204 0.47 
120 66 6 0.022 
a In 125I-MIBG therapies, 0.3 mg of 131I-MIBG is included 
b Platelet ratio is nadir level/level at outset of therapy 
c One kidney 
d Had bone marrow transplants 
European Journal of Nuclear Medicine Vol. 21, No. 1, January 1994 
48 
Absorbed dose was calculated following the MIRD formalism 
[18]. The equation for calculating the mean absorbed dose was: 
m 
where, D, in Gy, was the mean absorbed dose; A, in Bq-s, 
was the cumulated activity; Ai, in Gy-kg per Bq-s, was the mean 
energy emitted per unit cumulated activity for the i-th type radia- 
tion; 0i was the absorbed fraction for the i-th type of radiation; 
and m, in kg, was the mass of the target organ. 
The cumulated activity was obtained by integration under the 
patient's whole-body or blood time-activity curves. For time fol- 
lowing the last measured data point, an effective half-life was 
determined from the slope (obtained by linear regression analysis) 
of the last three measured data points. The area under this "tail" 
was obtained using the equation: 
A=1.443 × An x Tell, 
where, An, in Bq, was the activity of the last data point mea- 
sured at time n; and Tell, in seconds, was the calculated effective 
half-life. 
The mean energy emitted per unit cumulated activity was ob- 
tained from ICRU Report 32 [19]. The absorbed fractions for beta 
particles and other nonpenetrating radiations were assumed to be 
one. For the whole body, the absorbed fractions for gamma and 
other penetrating radiation were obtained from tables in MIRD 
Pamphlet No. 3 [20] assuming uniform distribution of the activity 
in an ellipsoid having the same mass as the patient. For blood, 
the absorbed fractions for gamma and other penetrating radiation 
were assumed to be equal to the absorbed fraction for the whole 
body. The time-activity curves for blood showed a more rapid 
disappearance of radiolabeled MIBG than those for the whole 
body. Thus, absorbed radiation doses to blood were always sub- 
stantially lower than those to the body. 
Treatments'. Therapeutic doses were also infused over 90 min. 
Therapeutic doses of 125I-MIBG included 0.037 GBq of 131I- 
MIBG to facilitate imaging of the distribution of the radiophar- 
maceutical. Whole-body retentions of the treatment doses were 
measured by an ion chamber at 1 m in the room of each patient. 
These measurements were almost entirely of radiations from 125I. 
The times of measurement were the same as for the pretherapy 
dosimetry, but the patients frequently were discharged 4 days after 
treatment and, in two instances, data were collected for only 3 
days. 
Of those receiving BII-MIBG, the first six patients had re- 
ceived 131I-MIBG in doses that varied according to the accumu- 
lating experience in what was then a new therapy [4]. As noted 
above, three additional patients were given 6.48-7.40 GBq of 
131I-MIBG, doses that had produced some, but not marked, de- 
clines in circulating platelets of the previous six subjects 
(Table 1). 
In the phase I/II trial of therapy with 125I-MIBG, a protocol 
was designed in which doses were to be escalated to find the 
maximum tolerable dose of this radiopharmaceutical, one that 
produced marked but tolerable and reversible toxicity. Initially, 
we believed that absorbed doses of whole-body radiation would 
best predict toxicity. Doses in the escalation protocol were to be 
75-124 cGy, 124-175 cGy, etc., each for groups of three patients. 
However, it soon became apparent that some doses in the 125 
cGy range produced marked thrombocytopenia, but others did 
not, and whole-body radiation doses proved to be inaccurate pre- 
dictors of toxicity. Subsequent doses were then aimed at the 120- 
130 cGy level to gain added information (Table 1). However, for 
two patients (#6, #7) the syntheses of 125I-MIBG produced doses 
for administration that would impart somewhat less than this tar- 
get for whole-body radiation. Nevertheless, since patients were 
prepared for, and anticipated treatment, we decided to proceed 
with the less than prescribed doses in these instances. 
Because previous experience had shown that thrombocyto- 
penia was the earliest sign of toxicity [1, 6, 12, 14], we adopted 
as the indices of toxicity the relative declines and the absolute 
levels of circulating platelets. These data are also included in 
Table 1. 
Data analyses. The two toxicity indices, lowest post-therapeutic 
level of circulating platelets (nadir) and relative change in plate- 
lets (platelet ratio, calculated as nadir/pretherapeutic platelet 
count), were compared to three predictive indices, whole-body 
absorbed dose in cGy, administered dose in GBq/kg of body 
weight, and administered dose in GBq/m 2 of body surface area. 
The logarithmic (base 10, hence log10) transformation was applied 
to the platelet ratio to produce a more linear relationship with the 
predictive indices [21]. The logit transformation {logit(p) = 
loglo[p/(1-p]}, which is known to improve the linearity of rela- 
tionships involving proportions [21], was also applied to the plate- 
let ratio, but the results were virtually identical to those involving 
the logm transformation and are not reported here. 
The quality of the comparisons between predictive and toxic- 
ity indices was assessed by the magnitude of the correlations and 
by visual examination of bivariate plots for leverage points (ob- 
servations far removed from the others along the horizontal axis 
which would artificially increase the size of the correlation coeffi- 
cient). If an observation was found to be a leverage point, the 
analysis was repeated with that value deleted, resulting in a con- 
servative estimate of the correlation coefficient. In all the ana- 
lyses, only the values of whole-body dose measured in GBq/kg 
and in GBq/m 2 for patient #6 treated with 131I-MIBG were found 
to exert undue influence on the regression (see Fig. 2). Patient 
#6 was an adult who weighed 56.6 kg and received 8.14 GBq, 
so that his predictive indices were relatively low, and he exhibited 
little or no toxicity. This patient's values were deleted from ana- 
lyses involving GBq/kg and GBq/m 2. 
All statistical calculations were performed using the Statistical 
Analysis System (SAS Institute, Cary, NC). p-Values were deter- 
mined by dividing the value of the regression coefficients by their 
standard errors and comparing the results to a t-distribution. If 
the correlation between a predictive index and a toxicity index 
was significant, the estimated toxic dose (in units of the predictive 
index) was calculated. For this calculation, toxicity was assumed 
to occur if the count declined beneath 20,000 platelets/gl or if 
the platelet ratio declined beneath 0.1. The estimated toxic dose 
was derived by inverting the regression equation: 
toxicity index=a + b x predictive index 
and inserting the given toxicity level to obtain: 
toxic dose=(toxicity level-a) / b. 
Correlations were also made between the absorbed radiation 
dose in blood and the indices of toxicity. However, data for the 
blood doses were not obtained for four patients treated with 131I- 
MIBG and for one patient treated with 125I-MIBG. 
Results 
Treatment with ~3JI-MIBG 
The  h ighes t  co r re l a t ions  b e t w e e n  p red ic t ive  and  tox ic i ty  
ind ices  we re  p r o d u c e d  for  the  p red ic t i ve  ind ices  
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Table 2. Correlations of predictive indices with toxicity indices 
Precdictive Correlation Nadir Nadir (log10) Ratio Ratio (log j0) 
index values 
l 311 GBq/kg r -0.48 -0.32 -0.47 -0.38 
P 0.23 0.44 0.24 0.35 
Toxicity . . . .  
GBq/m 2 r -0.76 -0.68 -0.74 -0.72 
P 0.03 0.06 0.04 0.05 
Toxicity 276 283 278 294 
cGy r -0.74 -0.86 -0.69 -0.79 
P 0.02 0.003 0.04 0.01 
Toxicity 277 292 290 270 
49 
[ 25l GBq/kg 
GBq/m 2 
cGy 
r -0.66 -0.78 -0.76 -0.80 
P 0.04 0.008 0.01 0.006 
Toxicity 31.2 28.8 31.3 27.3 
r -0.65 -0.77 -0.73 -0.81 
P 0.04 0.01 0.02 0.005 
Toxicity 773 724 779 675 
r -0.31 -0.37 -0.46 -0.41 
P 0.38 0.29 0.l 8 0.24 
Toxicity - - - 
Correlation coefficient (r), statistical significance of correlations 
(P), and estimate of toxic dose for different predictive and toxicity 
indices. Toxicity was assumed to occur at a platelet count ~< 
20,000 platelets/gl or at a nadir/pretreatment ratio < 0.1. Estimates 
of toxicity were not determined when P-value > 0.10. Sample 
size for all t25I-MIBG values is n=10. Sample size for all 131I- 
MIBG values is n=9, except for values related to GBq/kg and 
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Fig. 1. Logl0-transformed nadir of platelets in thousands versus 
dose of 131I-MIBG in cGy. The equation for the plotted regression 
line is log10 (nadir)=3.23 -0.0066 x cGy; r=-0.85, P=0.003 
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Fig. 2. Platelet nadir in thousands versus dose of ~3~I-MIBG in 
GBq/m 2. The equation for the plotted regression line is nadir=974 
-93.2 x GBq/m2; r=-0.76, P =0.03. Patient #6 (dose=5.1 GBq/m 2) 
was not included in the calculation of the regression line 
G B q / m  2 and c G y  (Table 2). The  va lue  o f  the log10 trans- 
fo rma t ion  on these indices  was di f f icul t  to assess ,  but  
the indices  that  p red ic t ed  toxici ty ,  10 .2-10 .8  G B q / m  2 
and 2 7 7 - 2 9 2  cGy,  were  cons is ten t  i r respec t ive  o f  the 
use o f  the t ransformat ion .  
The  larges t  cor re la t ion  be tween  p red ic t ive  and tox-  
ic i ty  ind ices  for  r31I-MIBG was that  be tween  whole-  
body  rad ia t ion  (in cGy)  and logl0- t ransformed p la te le t  
nadir, r - - -0 .85  (n=9, P=0.003)  (Fig.  1). I f  tox ic i ty  is 
def ined  as a p la te le t  count  o f  20 000/~tl or  less (or 20 
for  s impl i f ica t ion) ,  this r egress ion  is: loglo(nadir)=3.23 
- 0 . 0 0 6 6  x dose  in cGy;  and log10(20)=1.3 then predic ts  
tox ic i ty  at 292 cGy. 
G o o d  resul ts  were  also ach ieved  by  compar ing  the 
nadi r  to the p red ic t ive  index  G B q / m  2 0~--0 .76 ,  P=0.03)  
(Fig.  2). Toxic i ty  was p red ic t ed  at 10.2 G B q / m  2, a va lue  
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Fig. 3. Logt0-transformed platelet ratio (nadir/outset) versus dose 
of 125I-MIBG in GBq/m 2. The equation for the regression line is 
logm (ratio)=0,89-0.0756 x GBq/m:; r=-0.81, P=0.005 
Table 3. Effective half -lives of whole-body diagnostic and ther- 
apeutic doses of t25I-MIBG 
Patient Dx T Eft (h) Rx T Eft (h) Rx/Dx 
l 29.2 15.8 0.54 
2 a 30.7 35.9 1.17 
3 27.5 14.6 0.53 
4 35.4 25.1 0.71 
5 23.4 28,3 1.21 
6 31.9 25,1 0.79 
7 27.9 20.8 0.75 
8 29.4 41.4 1.41 
9 a 64.8 26.6 0.41 
10 20.2 21.1 1.04 
Mean 32.0 25.5 0.86 
SD 12.3 8.3 0.33 
a One kidney 
similar to the others derived for this predictive index. 
A similar correlation was obtained by comparing the 
platelet ratio to GBq/m 2 to give the regression: 
ratio=2.62-0.244 GBq/m2; then r=-0.74, P =0.04, and 
toxicity at a platelet ratio of 0.1 was predicted at 10.3 
GBq/m 2 (Table 2). 
Although data on absorbed radiation dose to blood 
were available for only four patients in this group, the 
correlation with the platelet ratio was r=-0.84. 
Treatment with ~25I-MIBG 
Unlike 131I-MIBG, none of the correlations between the 
various toxicity indices and cGy were statistically sig- 
nificant. However, the correlations between GBq/m 2 and 
GBq/kg were statistically significant, and were fairly 
consistent across toxicity indices. They also tended to 
agree with the values produced for 13q-MIBG. 
The highest correlation between predictive and toxic 
indices occurred when the logt0-transformed platelet 
ratio was compared with the dose of 125I-MIBG mea- 
sured in GBq/m a, r=-0.81 (n=10, P=0.005) (Fig, 3). 
This toxicity index also gave a lower predicted toxic 
dose (25.0 GBq/m 2 vs a mean of 28.1 GBq/m 2 for the 
other three toxicity indices). The result was largely be- 
cause the log~0 transformation tended to emphasize the 
very low ratio values, and therefore produced a lower 
predicted toxic dose. 
Since the effective half-life of 125I-MIBG is a major 
factor in calculating whole-body absorbed dose, the ef- 
fective half-lives of the pretherapeutic or diagnostic 
dose (made with ~3tI-MIBG) are shown in Table 3 for 
patients treated with ~25I-MIBG. Four patients (#2, #5, 
#8, and #10) had longer effective half-lives for the ther- 
apeutic dose than for the diagnostic dose, but, for all 
ten subjects, the mean effective half-life of the ther- 
apeutic dose (25.5 h) was less than that of the diagnostic 
dose (32.0 h). The standard deviation of the therapeutic 
doses was smaller than that of the diagnostic doses, and, 
of particular interest, is that one of the patients who 
had a nephrectomy (patient #9) exhibited a relatively 
long effective half-life (64.8 h) with the diagnostic dose, 
but the effective half-life of the therapeutic dose (26.6 
h) was close to the mean for this group of patients. The 
other patient who had unilateral nephrectomy as part of 
the surgical resection of tumor (#2) did not exhibit di- 
agnostic or therapeutic half-life values that deviated 
substantially from the respective means of the group, 
The same was true for the three patients who had prior 
bone marrow transplantations (#4, #6, #7). 
The correlations of the absorbed radiation to blood 
with either of the toxicity indices gave low coefficients, 
the highest being r=-0.17. 
Discussion 
If 131I-MIBG and 125I-MIBG are to be effective in the 
treatment of neuroblastoma, the doses of these 
radiopharmaceuticals must be larger than have generally 
been given in the past. To achieve the greatest benefit, 
~3~I-MIBG and t25I-MIBG must be given in the maxi- 
mum tolerable doses. Yet, previous experience had not 
enabled reliable calculations of such doses. Although 
treatments with large, marrow-destroying doses of ~>I- 
MIBG have been followed by bone marrow transplan- 
tation [22], this approach has not yet been widely ap- 
plied nor validated. Assuming marrow transplantation 
is not part of the protocol, the limiting factor will be 
hematopoietic toxicity. Leukopenia followed treatments 
with 131I-MIBG and 125I-MIBG, but, with the exception 
of one patient whose entire marrow function was lost, 
the relative decline in leukocytes was less than that of 
platelets and did not pose an immediate threat to health. 
Platelet production has been the function most sensitive 
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to the effects of radiation from the radiopharmaceuticals' 
[1, 6, 12, 14], and, thus, the concentrations of circulat- 
ing platelets have become the major index of toxicity. 
From our acquired data, we have demonstrated correla- 
tions between the level of thrombocytopenia and 
various indices of radiation dose so that bone marrow 
toxicity should be predictable with a reasonable degree 
of accuracy when either ~31I-MIBG or 125I-MIBG is ad- 
ministered. However, our calculations were made on 
patients who had little or no bone marrow involvement 
by neuroblastoma, and they may not apply if there was 
an increment in marrow radiation from radiolabeled 
MIBG concentrated in proximate tumor cells. 
Absorbed doses of radiation have been calculated for 
some individual organs for ~3~I-labeled monoclonal an- 
tibodies [23] and for H~In-labeled octreotide [24]. How- 
ever, such measurements require additional assumptions 
and, although they seem to give reliable results for 
groups of people, the error for an individual patient may 
be substantial. In any case, our goal was to find a rela- 
tively simple and reproducible index of the earliest and 
most serious toxicity from radiolabeled MIBG, i.e., 
thrombocytopenia. 
Although absorbed doses to bone marrow have been 
calculated by subtracting uptakes in tumor and liver 
from the whole-body retention of 131I-MIBG [25], the 
accuracy of such measurements is doubtful, especially 
since uptakes in organs and tumors are imprecise. Lack- 
ing any ready measurement of absorbed dose of radia- 
tion to the bone marrow, it was thought that whole-body 
dosimetry would give the highest level of correlation 
with the decline in circulating platelets. In the case of 
131I-MIBG therapy, the cGy of whole-body radiation 
was predictive of thrombocytopenia, but with only a 
small advantage over the simpler and more easily at- 
tained index of GBq/m 2 of body surface area. For ~25I- 
M1BG treatments, absorbed doses of whole-body radia- 
tion had virtually no value in forecasting the changes 
in circulating platelets. Yet, GBq/kg and GBq/m 2 each 
correlated with thrombocytopenia to give respectable r 
values. 
Why whole-body radiation doses should correlate 
with thrombocytopenia substantially less well than 
GBq/kg or GBq/m 2 after treatments with ~25I-MIBG is 
not clear. It is possible that the microdosimetry of ~25I- 
MIBG in the bone marrow may vary from patient to 
patient, but using MIRD formalism, the only difference 
of consequence in deriving the indices was that doses 
in cGy take into account the effective half-life of the 
radiopharmaceuticals within the patients. The effective 
half-lives of the therapeutic doses differed from those 
used in the dosimetry calculations, but these discrepan- 
cies would degrade the correlations with toxicity only 
if the differences between pretherapeutic effective half- 
life and therapeutic half-life varied from patient to 
patient. This type of variation did not seem pronounced 
in patients treated with ~25I-MIBG, but may have played 
a role in the outcome. The hydration of the patients 
could have varied between the times of dosimetry and 
therapy and differed among patients. The consequence 
of different states of hydration may have been a more 
prolonged or briefer retention than predicted for 1251- 
MIBG in the tissues, including the bone marrow, of 
patients, and these variations may have contributed to 
errors in predicting toxicity by the use of the absorbed 
dose of radiation calculated from the diagnostic data. 
Thus, whole-body dosimetry incorporated more data 
than GBq/kg and GBq/m 2 into an index of absorbed 
dose, but at the same time the added data introduced a 
greater variability that vitiated the use of cGy. Our 
whole-body dosimetry would probably have been more 
accurate if data had been acquired for one or two more 
days on the patients [25], but the limitations on patient 
expenses and the urgency for therapy dictated expe- 
diency in our protocol. 
From the limited blood data in this study, calcula- 
tions of radiation to blood appear to foretell the toxicity 
of 131I-MIBG as well. Following the injection of a di- 
agnostic dose of ~31I-MIBG, aspirates of bone marrow 
were obtained at the same time as blood specimens were 
drawn in three patients [14]; the respective concentra- 
tions of radioactivity were similar so that one might 
expect that blood dosimetry would reflect that in the 
marrow. However, blood dosimetry for 125I-MIBG had 
little or no correlation with the platelet levels following 
therapy with this agent. It is possible that radiation to 
the blood and body could increase consumption as well 
as decrease production of platelets, but there is no evi- 
dence that differing rates of loss of platelets play a 
major role in radiopharmaceutical treatments. There is 
still much to be learned about how ~25I-MIBG imparts 
its destructive energy, including at the microdosimetry 
level. 
The relative effects of ~25I-MIBG and ~3~I-MIBG on 
normal tissues can be compared. To induce platelet de- 
clines to 10% of the pretherapeutic levels or to 
20000/gl, the doses of 125I-MIBG, 27.3 GBq/m 2, were 
2.6-fold higher than those of 131I-MIBG, 10.5 GBq/m 2 
(each value an average of four correlations). In three 
patients of our study, prior bone marrow transplantation 
did not seem to make for greater susceptibility to throm- 
bocytopenia from radiopharmaceutical therapy. 
In summary, we recommend that, in treatments with 
~3~I-MIBG, the predictive index GBq/m 2 be used with 
either the nadir or platelet ratio, either with or without 
the use of the log10 transformation. When ~25I-MIBG is 
given as therapy, either GBq/kg or GBq/m 2 will usefully 
predict the log10-transformed platelet ratio. The use of 
the GBq/m 2 predictive index against the logj0-trans- 
formed platelet ratio produces acceptable results for 
both radiopharmaceutical treatments. 
In addition, this type of analysis may prove useful 
for therapies employing other types of radiophar- 
maceuticals; empirical observations often make useful 
guides. 
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